131 related articles for article (PubMed ID: 38037464)
1. Untargeted metabolomics identifies metabolic dysregulation of sphingolipids associated with aggressive chronic lymphocytic leukaemia and poor survival.
Nguyen Van Long F; Valcourt-Gendron D; Caron P; Rouleau M; Villeneuve L; Simonyan D; Le T; Sergerie R; Laverdière I; Vanura K; Guillemette C
Clin Transl Med; 2023 Dec; 13(12):e1442. PubMed ID: 38037464
[TBL] [Abstract][Full Text] [Related]
2. UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Allain EP; Rouleau M; Vanura K; Tremblay S; Vaillancourt J; Bat V; Caron P; Villeneuve L; Labriet A; Turcotte V; Le T; Shehata M; Schnabl S; Demirtas D; Hubmann R; Joly-Beauparlant C; Droit A; Jäger U; Staber PB; Lévesque E; Guillemette C
Br J Cancer; 2020 Jul; 123(2):240-251. PubMed ID: 32418995
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis.
Thurgood LA; Dwyer ES; Lower KM; Chataway TK; Kuss BJ
Br J Haematol; 2019 Apr; 185(1):65-78. PubMed ID: 30656643
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome.
Wagner A; Rouleau M; Villeneuve L; Le T; Peltier C; Allain ÉP; Beaudoin C; Tremblay S; Courtier F; Nguyen Van Long F; Laverdière I; Lévesque É; Banerji V; Vanura K; Guillemette C
Cells; 2023 May; 12(9):. PubMed ID: 37174695
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics Analysis Identifies Sphingolipids as Key Signaling Moieties in Appressorium Morphogenesis and Function in Magnaporthe oryzae.
Liu XH; Liang S; Wei YY; Zhu XM; Li L; Liu PP; Zheng QX; Zhou HN; Zhang Y; Mao LJ; Fernandes CM; Del Poeta M; Naqvi NI; Lin FC
mBio; 2019 Aug; 10(4):. PubMed ID: 31431550
[TBL] [Abstract][Full Text] [Related]
7. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
8. Bioactive sphingolipids in response to chemotherapy: a scope on leukemias.
Ekiz HA; Baran Y
Anticancer Agents Med Chem; 2011 May; 11(4):385-97. PubMed ID: 21453240
[TBL] [Abstract][Full Text] [Related]
9. Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells.
Rouleau M; Villeneuve L; Allain EP; McCabe-Leroux J; Tremblay S; Nguyen Van Long F; Uchil A; Joly-Beauparlant C; Droit A; Guillemette C
BMC Cancer; 2024 Apr; 24(1):410. PubMed ID: 38566115
[TBL] [Abstract][Full Text] [Related]
10. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
11. Management of chronic lymphocytic leukaemia.
Kalil N; Cheson BD
Drugs Aging; 2000 Jan; 16(1):9-27. PubMed ID: 10733261
[TBL] [Abstract][Full Text] [Related]
12. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody.
Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
Tumour Biol; 2016 Mar; 37(3):4143-57. PubMed ID: 26490985
[TBL] [Abstract][Full Text] [Related]
13. An LC/MS/MS method for the simultaneous determination of individual sphingolipid species in B cells.
Mi S; Zhao YY; Dielschneider RF; Gibson SB; Curtis JM
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Sep; 1031():50-60. PubMed ID: 27450899
[TBL] [Abstract][Full Text] [Related]
14. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans.
Martinez-Torres AC; Quiney C; Attout T; Boullet H; Herbi L; Vela L; Barbier S; Chateau D; Chapiro E; Nguyen-Khac F; Davi F; Le Garff-Tavernier M; Moumné R; Sarfati M; Karoyan P; Merle-Béral H; Launay P; Susin SA
PLoS Med; 2015 Mar; 12(3):e1001796. PubMed ID: 25734483
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia.
Trojani A; Di Camillo B; Tedeschi A; Lodola M; Montesano S; Ricci F; Vismara E; Greco A; Veronese S; Orlacchio A; Martino S; Colombo C; Mura M; Nichelatti M; Colosimo A; Scarpati B; Montillo M; Morra E
Cancer Biomark; 2011-2012; 11(1):15-28. PubMed ID: 22820137
[TBL] [Abstract][Full Text] [Related]
16. Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism.
Dielschneider RF; Eisenstat H; Mi S; Curtis JM; Xiao W; Johnston JB; Gibson SB
Leukemia; 2016 Jun; 30(6):1290-300. PubMed ID: 26859075
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
18. B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides.
Schwamb J; Feldhaus V; Baumann M; Patz M; Brodesser S; Brinker R; Claasen J; Pallasch CP; Hallek M; Wendtner CM; Frenzel LP
Blood; 2012 Nov; 120(19):3978-85. PubMed ID: 22927247
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
Br J Haematol; 2018 Oct; 183(2):212-224. PubMed ID: 30125946
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
